Source author record

Samuel Pawel

Samuel Pawel appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
1topics
3close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2026arXiv

Bayes Factor Group Sequential Designs

The Bayes factor, the data-based updating factor from prior to posterior odds, is a principled measure of relative evidence for two competing hypotheses. It is naturally suited to sequential data analysis in settings such as clinical trials and animal experiments, where early stopping for efficacy or futility is desirable. However, designing such studies is challenging because computing design characteristics, such as the probability of obtaining conclusive evidence or the expected sample size, typically requires computationally intensive Monte Carlo simulations, as no closed-form or efficient numerical methods exist. To address this issue, we extend results from classical group sequential design theory to sequential Bayes factor designs. The key idea is to derive Bayes factor stopping regions in terms of the z-statistic and use the known distribution of the cumulative z-statistics to compute stopping probabilities through multivariate normal integration. The resulting method is fast, accurate, and simulation-free. We illustrate it with examples from clinical trials, animal experiments, and psychological studies. We also provide an open-source implementation in the bfpwr R package. Our method makes exploring sequential Bayes factor designs as straightforward as classical group sequential designs, enabling experiments to rapidly design informative and efficient experiments.

preprint2022arXiv

When Evidence and Significance Collide

Null hypothesis statistical significance testing (NHST) is the dominant approach for evaluating results from randomized controlled trials. Whereas NHST comes with long-run error rate guarantees, its main inferential tool -- the $p$-value -- is only an indirect measure of evidence against the null hypothesis. The main reason is that the $p$-value is based on the assumption the null hypothesis is true, whereas the likelihood of the data under any alternative hypothesis is ignored. If the goal is to quantify how much evidence the data provide for or against the null hypothesis it is unavoidable that an alternative hypothesis be specified (Goodman & Royall, 1988). Paradoxes arise when researchers interpret $p$-values as evidence. For instance, results that are surprising under the null may be equally surprising under a plausible alternative hypothesis, such that a $p=.045$ result (`reject the null') does not make the null any less plausible than it was before. Hence, $p$-values have been argued to overestimate the evidence against the null hypothesis. Conversely, it can be the case that statistically non-significant results (i.e., $p>.05)$ nevertheless provide some evidence in favor of the alternative hypothesis. It is therefore crucial for researchers to know when statistical significance and evidence collide, and this requires that a direct measure of evidence is computed and presented alongside the traditional $p$-value.